Flag of the European Union EU Clinical Trials Register Help

Clinical trials for sanofi

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43876   clinical trials with a EudraCT protocol, of which   7294   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    2,176 result(s) found for: sanofi. Displaying page 1 of 109.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2015-005189-48 Sponsor Protocol Number: MPS01 Start Date*: 2015-11-17
    Sponsor Name:Sanofi Pasteur SA
    Full Title: Safety and Immunogenicity of Sanofi Pasteur Meningococcal (Groups A and C) Polysaccharide Vaccine versus Lanzhou Institute of Biological Products Meningococcal (Groups A and C) Polysaccharide Vacci...
    Medical condition: Meningococcal Disease
    Disease:
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2017-002988-18 Sponsor Protocol Number: EFC15068 Start Date*: 2018-11-26
    Sponsor Name:Sanofi-Aventis Recherche & Développement
    Full Title: A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of sarilumab in patients with giant cell arteritis
    Medical condition: Giant Cell Arteritis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004866 10018250 Giant cell arteritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) AT (Prematurely Ended) DK (Completed) HU (Completed) FR (Completed) SE (Prematurely Ended) EE (Prematurely Ended) ES (Prematurely Ended) NL (Prematurely Ended) PT (Completed) SI (Completed) BE (Prematurely Ended) HR (Completed) GB (GB - no longer in EU/EEA) NO (Completed) FI (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-005184-16 Sponsor Protocol Number: IPV26 Start Date*: 2015-11-17
    Sponsor Name:Sanofi Pasteur SA
    Full Title: Immunogenicity and Safety of Fractional Booster Dose of sanofi pasteur’s Inactivated Poliomyelitis Vaccine (IMOVAX Polio) Administered Intradermally versus Full Booster Dose of Inactivated Poliomye...
    Medical condition: Poliomyelitis
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2015-005183-42 Sponsor Protocol Number: IPV25 Start Date*: 2015-11-17
    Sponsor Name:Sanofi Pasteur SA
    Full Title: Immunogenicity and Safety of Fractional Doses of Sanofi Pasteur’s Inactivated Poliomyelitis Vaccine (IMOVAX Polio™) Administered Intradermally versus Full Doses of Inactivated Poliomyelitis Vaccine...
    Medical condition: Poliomyelitis
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2015-005185-34 Sponsor Protocol Number: IPV29 Start Date*: 2015-11-19
    Sponsor Name:Sanofi Pasteur China
    Full Title: Safety study of IMOVAX Polio in selected cities in China, an observational post marketing study
    Medical condition: Poliomyelitis
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2016-001964-13 Sponsor Protocol Number: HAF85 Start Date*: 2016-05-06
    Sponsor Name:Sanofi Pasteur Korea Ltd
    Full Title: Regulatory Post-Marketing Surveillance (PMS) Study for AVAXIM 160U (Hepatitis A Vaccine)
    Medical condition: Hepatitis A
    Disease:
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2015-005186-23 Sponsor Protocol Number: IPV34 Start Date*: 2015-11-19
    Sponsor Name:Sanofi Pasteur China
    Full Title: Large scale safety study of IMOVAX Polio in selected cities in China, an observational post marketing study
    Medical condition: Poliomyelitis
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2004-003809-25 Sponsor Protocol Number: L-9134 Start Date*: 2004-12-20
    Sponsor Name:Sanofi-Synthelabo Co. Ltd.
    Full Title: Comparison of the efficacy and tolerability of drotaverine 80 mg or ibuprofen 400 mg administered alone with their combination for the treatment of primary and secondary dysmenorrhea
    Medical condition: A NO-SPA és az ibuprofen kombinációja elfogadott és Magyarországon gyakran használták a nőgyógyászati gyakorlatban sok évvel ezelőtt. A kombináció használatával kapcsolatos súlyos mellékhatásról ne...
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: HU (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-001707-53 Sponsor Protocol Number: CYD13 Start Date*: 2014-05-26
    Sponsor Name:Sanofi Pasteur SA
    Full Title: Immunogenicity and Safety of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Children and Adolescents in Latin America
    Medical condition: Prevention of symptomatic dengue disease
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2011-005698-21 Sponsor Protocol Number: EFC11570 Start Date*: 2013-03-05
    Sponsor Name:sanofi-aventis Recherche & Développement
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Effect of Alirocumab (SAR236553/REGN727) on the Occurrence of Cardiovascular Events in Patients Who Have Recentl...
    Medical condition: Acute coronary syndrome
    Disease: Version SOC Term Classification Code Term Level
    19.0 10007541 - Cardiac disorders 10051592 Acute coronary syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) SE (Completed) BE (Completed) NO (Completed) EE (Completed) LT (Completed) HU (Completed) ES (Completed) CZ (Completed) LV (Completed) DE (Completed) IT (Completed) BG (Completed) FI (Completed) AT (Completed) PT (Completed) DK (Completed) NL (Completed) PL (Completed) SK (Completed) SI (Completed) HR (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2015-005191-18 Sponsor Protocol Number: HAF78 Start Date*: 2015-11-19
    Sponsor Name:Sanofi Pasteur SA
    Full Title: Immunogenicity and Safety of Sanofi Pasteur’s AVAXIM 80U Pediatric Vaccine Administered in Healthy Adolescents, Children and Toddlers in People’s Republic of China Followed by a Booster Dose 6 Mont...
    Medical condition: Hepatitis A
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2015-005197-38 Sponsor Protocol Number: TD9707-LT Start Date*: 2015-11-19
    Sponsor Name:Sanofi Pasteur Limited
    Full Title: Six-Month, One-Year, Three-Year, Five-Year and Ten-Year Data on the Long-Term Immunogenicity of Td-mIPV, Tdap-vIPV, Td, aP and Tdap in Adolescents and Adults
    Medical condition: Pertussis Tetanus Diphtheria
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2005-002789-12 Sponsor Protocol Number: U05-PnPS-403 Start Date*: 2005-09-28
    Sponsor Name:Sanofi Pasteur MSD S.N.C
    Full Title: A double blind comparative and randomised study in healthy adults of the safety, tolerability, and immunogenicity of PNEUMOVAX®II formulated with either all new process polysaccharides or all curre...
    Medical condition: Prevention of invasive pneumococcal disease (IPD)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-004660-37 Sponsor Protocol Number: LACAC_L_03732 Start Date*: 2015-03-25
    Sponsor Name:Sanofi
    Full Title: Monocentric Study, Phase III, for Safety Dermatological Evaluation: Acceptability With Gynecological Follow up - Dermacyd Tina Gel Sweet Flower
    Medical condition: Healthy volunteers (hygiene)
    Disease: Version SOC Term Classification Code Term Level
    17.1 10042613 - Surgical and medical procedures 10053339 Routine health maintenance PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2014-004662-26 Sponsor Protocol Number: LACAC_L_04298 Start Date*: 2015-03-25
    Sponsor Name:Sanofi
    Full Title: Safety Dermatological Evaluation: genital Mucosa Irritation - Product tested: Dermacyd PH_DETINLYN Sweet Flower.
    Medical condition: Healthy volunteers (hygiene)
    Disease: Version SOC Term Classification Code Term Level
    17.1 10042613 - Surgical and medical procedures 10053339 Routine health maintenance PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2014-004661-25 Sponsor Protocol Number: LACAC_L_03735 Start Date*: 2015-03-25
    Sponsor Name:Sanofi
    Full Title: Monocentric Study, Phase III, for Safety Dermatological Evaluation: Acceptability With Gynecological Follow up - Dermacyd Tina Gel Tangerina Mix
    Medical condition: Healthy volunteers (hygiene)
    Disease: Version SOC Term Classification Code Term Level
    17.1 10042613 - Surgical and medical procedures 10053339 Routine health maintenance PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2014-004659-30 Sponsor Protocol Number: PKM6270 Start Date*: 2015-03-17
    Sponsor Name:sanofi-aventis
    Full Title: Four-week, open-label, multicenter, randomized, parallel-group study to investigate the pharmacokinetics, safety, tolerability and the effects on leak point pressure of 2 oral doses of alfuzosin (0...
    Medical condition: Urinary Bladder Neurogenic
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2014-004664-38 Sponsor Protocol Number: LACAC_L_04304 Start Date*: 2015-03-25
    Sponsor Name:Sanofi
    Full Title: Safety Dermatological Evaluation: genital mucosa irritation - Product tested: Dermacyd PH_DETINLYN Tangerine Mix.
    Medical condition: Healthy volunteers (hygiene)
    Disease: Version SOC Term Classification Code Term Level
    17.1 10042613 - Surgical and medical procedures 10053339 Routine health maintenance PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2014-004666-14 Sponsor Protocol Number: LACAC_L_04678 Start Date*: 2015-03-25
    Sponsor Name:Sanofi
    Full Title: Safety Dermatological Evaluation: acceptability with pediatric follow up – Dermacyd Infantile LACAC_L_04678
    Medical condition: Healthy volunteers (hygiene)
    Disease: Version SOC Term Classification Code Term Level
    17.1 10042613 - Surgical and medical procedures 10053339 Routine health maintenance PT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2014-004663-20 Sponsor Protocol Number: LACAC_L_04301 Start Date*: 2015-03-25
    Sponsor Name:Sanofi
    Full Title: Safety Dermatological Evaluation: genital mucosa irritation - Product tested: Dermacyd PH_DETINBACK Sweet Flower
    Medical condition: Healthy volunteers (hygiene)
    Disease: Version SOC Term Classification Code Term Level
    17.1 10042613 - Surgical and medical procedures 10053339 Routine health maintenance PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 11 05:01:30 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA